By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Novartis' Q2 beat was driven by strong performance in oncology and immunology, but the company faces significant challenges from patent cliffs and increasing expenses, casting doubt on its ability to meet guidance and re-rate its valuation.
Risk: Simultaneous patent cliffs and increasing expenses, including a jump in the effective tax rate, threaten to derail Novartis' growth and earnings outlook.
Opportunity: The company's shift towards high-growth oncology and immunology assets, if successful, could mitigate the impact of patent cliffs and drive long-term growth.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Novartis reported second-quarter net sales of $14.4 billion on Tuesday, up 3% in dollar terms and 1% in constant currencies, as strong demand for cancer and multiple sclerosis treatments helped the Swiss drugmaker return to sales growth despite a steep drop in its top-selling heart drug.
Core operating income — the company's preferred profit measure, which strips out special items — came in flat year-over-year at $5.94 billion. Analyst expectations had placed that figure at around $5.31 billion, according to the Wall Street Journal. Net income fell 19% to $3.26 billion, weighed down by higher income taxes and interest expense.
The growth was driven by a cluster of fast-expanding medicines. Breast cancer drug Kisqali posted sales of $1.7 billion, up 43% in constant currencies, while leukemia treatment Scemblix rose 89% to $562 million. Multiple sclerosis drug Kesimpta grew 32% to $1.42 billion, and prostate cancer treatment Pluvicto climbed 43% to $651 million.
Offsetting those gains was a sharp deterioration in Entresto, the heart failure drug that had been Novartis's top revenue generator. Entresto sales fell 50% in the quarter to $1.18 billion, hurt by generic competition in the United States, according to Yahoo News. The drug is set to lose patent exclusivity in Europe beginning in November, though Novartis said it expects the sales decline to be less steep in the second half of the year. Platelet-booster Promacta and leukemia treatment Tasigna also faced significant generic erosion, falling 64% and 57%, respectively.
Novartis reaffirmed its full-year 2026 guidance, forecasting low single-digit net sales growth and a low single-digit decline in core operating income in constant currencies.
Chief Executive Officer Vas Narasimhan said the company is pursuing further acquisitions to shore up its pipeline. Novartis plans to focus on smaller deals while remaining open to larger transactions, Narasimhan said on a call with reporters. In July, Novartis agreed to acquire Myricx Bio, a biotechnology company developing antibody-drug conjugates targeting cancer, the company said. The deal is expected to close in the second half of 2026.
The company also flagged several pipeline milestones in the quarter. Regulators in Europe and Japan approved Rhapsido for chronic spontaneous urticaria, while the European Commission approved Itvisma as a gene replacement therapy for a broad population of patients with spinal muscular atrophy. Novartis also submitted a regulatory application to the FDA seeking accelerated approval of del-zota for Duchenne muscular dystrophy.
Novartis stock rose 1.9% in European afternoon trading Tuesday.
Four leading AI models discuss this article
"Strong oncology/MS growth is real but insufficient to fully offset generic erosion and a flat core OI outlook, leaving NVS valuation range-bound near-term."
Novartis (NVS) Q2 beat on core operating income ($5.94B vs $5.31B expected) masks underlying fragility. Oncology (Kisqali +43%, Scemblix +89%, Pluvicto +43%) and Kesimpta (+32%) delivered strong growth, yet a 50% plunge in flagship Entresto to $1.18B due to U.S. generics, plus 57-64% drops in Promacta/Tasigna, dragged overall sales to just +1% constant currency. Reaffirmed low-single-digit sales growth and core OI decline guidance looks conservative but leaves little margin for error on pipeline delivery. The 1.9% stock pop reflects relief on the beat, yet patent cliffs and tax/interest pressures warrant caution.
The strongest case against a neutral-to-bearish view is that oncology and MS franchises are scaling rapidly with high gross margins; if Kisqali and Scemblix continue 40%+ trajectories and new launches (Rhapsido, Itvisma, del-zota) hit, they can more than offset the Entresto/EU patent losses, supporting re-rating beyond current 11-12x forward P/E.
"Novartis has successfully de-risked its revenue profile by pivoting to high-growth oncology, though the valuation now depends entirely on the clinical success of its recent M&A acquisitions."
Novartis is successfully navigating a high-stakes transition, trading legacy blockbuster revenue for high-growth oncology and immunology assets. While the 50% collapse in Entresto sales is painful, the 43% surge in Kisqali and 32% growth in Kesimpta confirm the pipeline shift is working. The beat on core operating income—nearly 12% above consensus—demonstrates operational discipline despite the top-line headwinds from generic erosion. However, the market is ignoring the execution risk in the M&A strategy; relying on smaller bolt-ons like Myricx Bio to replace multi-billion dollar revenue gaps requires a high success rate in clinical trials that historically rarely materializes at scale.
The rapid erosion of legacy assets like Entresto and Promacta may outpace the growth of new therapies, leading to a structural margin compression that the current 'low single-digit' guidance fails to fully capture.
"Novartis is experiencing a portfolio transition that full-year guidance (low single-digit sales growth, declining core operating income) confirms is not yet profitable enough to offset legacy drug collapse."
Novartis beat on core operating income (+12% vs. consensus) and is growing oncology/immunology revenues robustly—Kisqali +43%, Scemblix +89%, Pluvicto +43%. But the headline obscures a portfolio in structural decline: Entresto collapsed 50%, Tasigna -57%, Promacta -64%. These aren't temporary setbacks; they're patent cliffs hitting simultaneously. The company is guiding to low single-digit sales growth and declining core operating income for full-year 2026—a contraction signal masked by Q2 beat optics. Acquisition strategy (Myricx Bio) signals pipeline anxiety, not confidence.
The oncology franchise is genuinely accelerating and now represents a larger revenue base than the legacy heart drugs; if Kisqali, Scemblix, and Pluvicto sustain 40%+ growth through 2027, the portfolio math flips positive despite Entresto's death.
"The key claim is that Novartis' Q2 beat can only be sustained if Entresto's margin erosion slows and the cancer/MS pipeline translates into durable revenue; otherwise the beat is a temporary reprieve."
Novartis' Q2 beat rests on cancer and MS franchises, with Kisqali at $1.7B (+43% CC), Kesimpta $1.42B (+32%), Scemblix $0.56B (+89%), and Pluvicto $0.65B (+43%). Entresto plunged 50% to $1.18B on US generics, with Europe patent expiry looming. The top-line strength masks margin risk: core operating income was flat at $5.94B despite sales, hinting at higher costs or unfavorable mix. Guidance remains modest: low-single-digit net-sales growth and a low-single-digit decline in core income in constant currencies. Pipeline optionality from Myricx Bio and new approvals is meaningful but uncertain timing; real earnings leverage depends on sustained productivity and payer access.
Against that, the strongest counter is bullish: the franchise breadth (Kisqali, Kesimpta, Scemblix, Pluvicto) provides durability even if Entresto declines, and regulatory approvals plus M&A could lift long-run earnings beyond the guided range.
"Tax and interest headwinds plus clinical concentration in bolt-on M&A limit re-rating potential even if oncology scales."
Claude correctly flags simultaneous patent cliffs, yet all four underplay the tax/interest expense surge already embedded in the core OI decline guidance. With effective tax rate jumping to ~18% and net financials worsening, even sustained 40% oncology growth may only stabilize EPS, not re-rate the 11.6x multiple. Myricx Bio adds clinical risk concentration nobody quantified.
"Novartis faces structural margin compression as it replaces high-margin legacy revenue with R&D-heavy oncology assets."
Grok, your focus on the 18% tax rate is vital, but you're missing the bigger picture: Novartis is effectively buying its way out of the patent cliff. While Claude worries about pipeline anxiety, the real risk is the 'margin trap.' By shifting from high-margin legacy blockbusters to oncology, they are trading high-margin, low-cost drugs for high-cost, R&D-intensive therapies. The 11.6x P/E isn't a discount; it’s a fair reflection of structural margin compression that will persist regardless of top-line growth.
"Margin compression from portfolio mix is plausible but unproven; tax/interest drag is quantifiable and underexplored."
Gemini's margin-trap thesis assumes oncology gross margins structurally underperform legacy drugs—but Kisqali and Scemblix pricing power in first-line settings suggests otherwise. The real issue: Novartis hasn't disclosed oncology-specific gross margins. Without that data, claiming margin compression is speculative. Grok's tax/interest headwind is concrete; Gemini's margin story needs numbers or it's narrative.
"Gemini's margin-trap thesis rests on undisclosed oncology gross margins and assumes compression that isn't proven; if Kisqali/Scemblix pricing power persists and offset tax headwinds, margins may stay resilient, challenging a negative re-rating case."
Gemini, your 'margin trap' critique hinges on oncology margins falling in lockstep with Entresto erosion. That’s an assumption. Novartis has not disclosed oncology gross margins, so the premise is speculative. If Kisqali/Scemblix pricing power and higher-margin Pluvicto access persist, incremental margins could hold better than you expect. Also, the tax/interest headwinds Grok highlighted are real, so any margin gains from a favorable mix need to outpace those headwinds to drive re-rating. Risk remains payer access and trial outcomes.
Novartis' Q2 beat was driven by strong performance in oncology and immunology, but the company faces significant challenges from patent cliffs and increasing expenses, casting doubt on its ability to meet guidance and re-rate its valuation.
The company's shift towards high-growth oncology and immunology assets, if successful, could mitigate the impact of patent cliffs and drive long-term growth.
Simultaneous patent cliffs and increasing expenses, including a jump in the effective tax rate, threaten to derail Novartis' growth and earnings outlook.